Vanda Pharmaceuticals IncNASDAQ:VNDA
- LAST PRICE5.4100
- TODAY'S CHANGE (%)-0.1700 (-3.0466%)
- Bid / Lots5.4100/ 4
- Ask / Lots5.4200/ 6
- Open / Previous Close5.5800 / 5.5800
- Day Range
- 52 Week Range
- Volume289,932
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VNDA |
|---|---|---|
| 09:32 ET | 14632 | 5.54 |
| 09:34 ET | 2000 | 5.535 |
| 09:36 ET | 600 | 5.54 |
| 09:38 ET | 14082 | 5.55 |
| 09:39 ET | 600 | 5.56 |
| 09:41 ET | 300 | 5.56 |
| 09:43 ET | 535 | 5.56 |
| 09:45 ET | 4000 | 5.56 |
| 09:48 ET | 2280 | 5.56 |
| 09:50 ET | 1200 | 5.565 |
| 09:52 ET | 300 | 5.55 |
| 09:54 ET | 12063 | 5.57 |
| 09:56 ET | 3500 | 5.57 |
| 09:57 ET | 2400 | 5.53 |
| 09:59 ET | 1450 | 5.525 |
| 10:01 ET | 600 | 5.515 |
| 10:03 ET | 4471 | 5.51 |
| 10:06 ET | 500 | 5.5 |
| 10:08 ET | 930 | 5.49 |
| 10:10 ET | 901 | 5.48 |
| 10:12 ET | 3071 | 5.47 |
| 10:14 ET | 700 | 5.4699 |
| 10:15 ET | 9612 | 5.459 |
| 10:17 ET | 2060 | 5.46 |
| 10:19 ET | 1300 | 5.4589 |
| 10:21 ET | 27808 | 5.44 |
| 10:24 ET | 1321 | 5.445 |
| 10:26 ET | 100 | 5.44 |
| 10:28 ET | 8267 | 5.44 |
| 10:30 ET | 2200 | 5.435 |
| 10:32 ET | 20196 | 5.4361 |
| 10:33 ET | 2504 | 5.45 |
| 10:35 ET | 3675 | 5.455 |
| 10:37 ET | 2458 | 5.445 |
| 10:39 ET | 2845 | 5.445 |
| 10:42 ET | 900 | 5.44 |
| 10:44 ET | 8549 | 5.425 |
| 10:46 ET | 38433 | 5.395 |
| 10:48 ET | 3055 | 5.39 |
| 10:50 ET | 1951 | 5.3903 |
| 10:51 ET | 6147 | 5.395 |
| 10:53 ET | 800 | 5.39 |
| 10:55 ET | 5996 | 5.395 |
| 10:57 ET | 22216 | 5.39 |
| 11:00 ET | 1300 | 5.395 |
| 11:02 ET | 7431 | 5.405 |
| 11:04 ET | 3802 | 5.4274 |
| 11:06 ET | 5672 | 5.43 |
| 11:08 ET | 899 | 5.43 |
| 11:09 ET | 476 | 5.43 |
| 11:11 ET | 4270 | 5.41 |
Yesterday
*DJ Federal Court Allows Vanda's HETLIOZ Patent Lawsuit to Proceed Against Teva and Apotex, from 8:02AM ET on Monday Jul 01, 2024 by Dow Jones
8:02AM ET on Monday Jul 01, 2024 by Dow JonesFederal Court Allows Vanda's HETLIOZ(R) Patent Lawsuit to Proceed against Teva and Apotex, from 8:01AM ET on Monday Jul 01, 2024 by Dow Jones
8:01AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 26, 2024
DJ Future Pak Withdraws Offer to Buy Vanda Pharmaceuticals, from 6:26PM ET on Wednesday Jun 26, 2024 by Dow Jones
6:26PM ET on Wednesday Jun 26, 2024 by Dow Jones*DJ Future Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals, from 5:47PM ET on Wednesday Jun 26, 2024 by Dow Jones
5:47PM ET on Wednesday Jun 26, 2024 by Dow Jones
Jun 20, 2024
DJ Vanda Shares Fall Premarket After Company Rejects Takeover Bids, from 6:18AM ET on Thursday Jun 20, 2024 by Dow Jones
6:18AM ET on Thursday Jun 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vanda Pharmaceuticals Inc | 324.7M | -64.0x | -37.98% |
Akebia Therapeutics Inc | 208.4M | -4.3x | --- |
Anika Therapeutics Inc | 383.3M | -4.9x | --- |
Agenus Inc | 350.5M | -1.3x | --- |
Revance Therapeutics Inc | 268.4M | -0.7x | --- |
Sutro Biopharma Inc | 249.5M | -1.5x | --- |
Company Information
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Contact Information
- Headquarters
- SUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON, DC, United States 20037
- Phone
- 202-734-3400
- Fax
- 202-296-1450
Executives
- Chairman of the Board, President, Chief Executive Officer
- Mihael Polymeropoulos
- Chief Financial Officer, Senior Vice President, Treasurer
- Kevin Moran
- Senior Vice President, Chief Marketing Officer
- Joakim Wijkstrom
- Senior Vice President, General Counsel, Secretary
- Timothy Williams
- Senior Vice President - Business Development
- Gunther Birznieks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $324.7M |
|---|---|
Revenue (TTM) | $177.6M |
Shares Outstanding | 58.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-0.08 |
Book Value | $9.47 |
P/E Ratio | -64.0x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -14.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
